AllSight
Companies · LNTH · In Vitro & In Vivo Diagnostic Substances

Lantheus Holdings, Inc. (LNTH)

Lantheus Holdings, Inc. (LNTH) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

Lantheus Holdings, Inc. (LNTH) stock — financials & valuation

Key numbers for Lantheus Holdings, Inc. (LNTH): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 63/100 — a percentile rank of Lantheus Holdings, Inc.’s fundamentals against Manufacturing peers, weakest on valuation. A quality ranking, not a price prediction.

Market cap$6.5B
P / E23.6×
P / S4.2×
EV / EBITDA16.6×
Gross margin60.1%
Operating margin19.4%
Net margin17.7%
Return on equity21.0%
ROIC17.8%
Revenue growth2.3%
Debt / equity0.4×
Dividend yield0.0%

Is Lantheus Holdings, Inc. overvalued? P/E looks fair vs its 5-year range; P/S looks fair vs its 5-year range; EV/EBITDA looks fair vs its 5-year range; P/B looks fair vs its 5-year range.

Independent of the events above — derived from Lantheus Holdings, Inc.’s own financial statements and shown as context, never as advice.

Sep 21, 2026Antitrust review reset
Lantheus resets FTC review clock for Curium merger without changing closing target
Aug 6, 2026
Revenue and adjusted EPS beat consensus, but PYLARIFY slipped and guidance vanished.
Related companies in In Vitro & In Vivo Diagnostic Substances
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact